Ashley Grossman: Research highlights from 2022 in neuroendocrine tumours

Thyroid nodules arising in the isthmus are more likely to be malignant and demonstrate more aggressive behavior relative to thyroid nodules from either thyroid lobe. touchENDOCRINOLOGY were joined by Dr Sina Jasim (Washington University, St Louis, MO, USA) to discuss the main findings of her study presented at ENDO23. The abstract ‘THU-680 – Cytologic And […]

New exciting therapies for neuroendocrine tumours include the introduction of RET inhibitors for medullary thyroid cancer and belzutifan for metastatic pancreatic neuroendocrine tumours. We were delighted to speak with our editorial board member Prof. Ashley Grossman (University of Oxford, Oxford, UK) around this year’s research highlights in these topics and what to look out for […]

It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG for pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]